Non-P-glycoprotein-mediated Multidrug Resistance in a Small Cell Lung Cancer Cell Line: Evidence for Decreased Susceptibility to Drug-induced DNA Damage and Reduced Levels of Topoisomerase II

Cancer Research

Volumn 51, Issue 13, 1991, Pages 3345-3352

  Cole, Susan P C ^a   Chanda, Eva R ^a   Dicke, Franciscus P ^a   Gerlach, James H ^a   Mirski, Shelagh E L ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DAUNORUBICIN; DNA TOPOISOMERASE; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; GRAMICIDIN D; VINBLASTINE;

ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DRUG RESISTANCE; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; TUMOR CELL LINE;

BASE SEQUENCE; CARCINOMA, SMALL CELL; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE; ETOPOSIDE; GENE EXPRESSION; HUMAN; IN VITRO; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDES; P-GLYCOPROTEIN; SUPPORT, NON-U.S. GOV'T; TUMOR CELLS, CULTURED;

EID: 0025939987     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Bleehen, N. M. Lung cancer-still a long road ahead. Br. J. Cancer, 61:493-494, 1990.
2. Williams, C. J. Chemotherapy of non-small cell lung caner. Br. J. Cancer, 60: 9-11, 1989.
3. Bergh, J., Nygren, P., and Larsson, R. Mechanisms for acquired cytotoxic drug resistance in human small cell lung cancer and the potential utilization of resistance modifiers-a review with focus on in vitro studies. Lung Cancer, 6:9-15, 1990.
4. Gerlach, J. H., Endicott, J. A., Juranka. P. F., Henderson, G., Sarangi, F., Deuchars, K. L., and Ling, V. Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance. Nature (Lond.), 324: 485-489, 1986.
5. Ma, D. D., Davey, R. A., Harman, D. H., Isbister, J. P., Scurr, R. D., Mackertich, S. M., Dowden, G., and Bell. D. R. Detection of a multidrug resistant phenotype in acute non-lymphoblastic leukemia. Lancet, /: 135-137, 1987.
6. Gerlach, J. H., Bell, D. R., Karakousis, C., Slocum, H. K., Kartner, N., Rustum, Y. M., Ling, V., and Baker, R. M. P-glycoprotein in human sarcoma: evidence for multidrug resistance. J. Clin. Oncol., 5: 1452-1460, 1987.
7. Goldstein, L. J., Galski, H., Fojo, A., Willingham, M., Lai, S.-L., Gazdar, A., Pirker, R., Green, A., Crist, W., Brodeur, G. M., Lieber, M., Cossman, J., Gottesman. M. M., and Pastan, I. Expression of a multidrug resistance gene in human cancers. J. Natl. Cancer Inst., 81: 116-124, 1989.
8. Lai, S.-L., Goldstein, L. J., Gottesman, M. M., Pastan, I., Tsai, C.-M., Johnson, B. E., Mulshine, J. L., Ihde, D. C., Kayser, K., and Gazdar, A. F. MDRI gene expression in lung cancer. J. Natl. Cancer Inst., 81: 1144-1150, 1989.
9. Mirski, S. E. L., Gerlach, J. H., and Cole, S. P. C. Multidrug resistance in a human small cell lung cancer cell line selected in Adriamycin. Cancer Res., 47: 2594-2598, 1987.
10. Minato, K., Kanazawa, F., Nishio, K., Nakagawa, K., Fujiwara, Y., and Saijo, N. Characterization of an etoposide-resistant human small-cell lung cancer cell line. Cancer Chemother. Pharmacol., 26: 313-317, 1990.
11. Reeve, J. G., Rabbitts, P. H., and Twentyman, P. R. Amplification and expression of mdr1 gene in a multidrug resistant variant of small cell lung cancer cell line NCI-H69. Br. J. Cancer, 60: 339-342, 1989.
12. Zijlstra, J. G., de Vries, E. G. E., and Mulder, N. H. Multifactorial drug resistance in an Adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res., 47: 1780-1784, 1987.
13. Jensen, P. B., Vindelov, L., Roed, H., Demant, E. J. F., Sehested, M., Skovsgaard, T., and Hansen, H. H. In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL). Br. J. Cancer, 60: 838-844, 1989.
14. Cole, S. P. C., Downes, H. F., Mirski, S. E. L., and Clements, D. J. Alterations in glutathione and glutathione-related enzyme in a multidrug resistant small cell lung cancer cell line. Mol. Pharmacol., 37: 192-197, 1990.
15. de Jong, S., Zijlstra, J. G., de Vries, E. G. E., and Mulder, N. H. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an Adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res., 50: 304-309, 1990.
16. Cole, S. P. C. Patterns of cross-resistance in a multidrug-resistant small-cell lung carcinoma cell line. Cancer Chemother. Pharmacol., 26:250-256,1990.
17. Cole, S. P. C., Downes, H. F., and Slovak, M. L. Effect of calcium antagonists on the chemosensitivity of two multidrug resistant human tumour cell lines which do not overexpress P-glycoprotein. Br. J. Cancer, 59: 42-46, 1989.
18. Trent, J. M., Meltzer, P. S., Slovak, M. L., Hill, A. B., Dalton, W. S., Beck, W. T., and Cole, S. P. C. Cytogenetic and molecular biological alterations associated with anthracycline resistance. In: P. V. Woolley III and K. D. Tew (eds.). Mechanisms of Drug Resistance in Neoplastic Cells, pp. 259-276. San Diego, CA: Academic Press, 1988.
19. Dalton, W. S., Durie, B. G. M., Alberts, D. S., Gerlach, J. H., and Cress, A. E. Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res., 46: 5125-5130, 1986.
20. Archer, T. K., Tam, S-P., Deugau, K. V., and Deeley, R. G. Apolipoprotein C-II mRNA levels in primate liver. J. Biol. Chem., 260: 1676-1681, 1985.
21. Lee, W. H., Wheatley, W., Benedict, W. F., Huang, C.-M., and Lee, E.Y.-H.P. Purification, biochemical characterization, and biological function of human esterase D. Proc. Natl. Acad. Sci. USA, 83:6790-6794, 1986.
22. Noonan, K. E., Beck, C., Holzmayer, T. A., Chin, J. E., Wunder, J. S., Andrulis, I. L., Gazdar, A. F., Willman, C. L., Griffith, B., Von Hoff, D. D., and Roninson, I. B. Quantitative analysis of MDRI (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc. Natl. Acad. Sci. USA, 87: 7160-7164, 1990.
23. Murphy, L. D., Herzog, C. E., Rudick, J. B., Fojo, A. T., and Bates, S. E. Use of the polymerase chain reaction in the quantitation of mdr-I gene expression. Biochemistry, 29: 10351-10356, 1990.
24. Doyle, A., Martin, W. J., Funa, K., Gazdar, A., Carney, D., Martin, S. E., Linnoila, I., Cuttitta, F., Mulshine, J., Bunn, P., and Minna, J. Markedly decreased expression of Class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. J. Exp. Med., 161: 1135-1151, 1985.
25. Gough, N. M. Rapid and quantitative preparation of cytoplasmic RNA from small numbers of cells. Anal. Biochem., 173:93-95, 1988.
26. Kohn, K. W., Ewig, R. A. G., Erickson, L. C., and Zwelling, L. A. Measurement of strand breaks and cross-links by alkaline elution. In: E. C. Friedberg, and P. C. Hanawalt (eds.), DNA Repair. A Laboratory Manual of Research Procedures, pp. 379-401. New York: Marcel Dekker, Inc., 1981.
27. Filipski, J., and Kohn, K. W. Ellipticine-induced protein-associated DNA breaks in isolated LI210 nuclei. Biochim. Biophys. Acta, 698: 280-286, 1982.
28. Towbin, H., Staehelin, T., and Gordon, J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA, 76: 4350-4354, 1979.
29. Sullivan, D. M., Latham, M. D., Rowe, T. C., and Ross, W. E. Purification and characterization of an altered topoisomerase II from a drug-resistant Chinese hamster ovary cell line. Biochemistry, 28: 5680-5687, 1989.
30. Pommier, Y., Schwartz, R. E., Zwelling, L. A., and Kohn, K. W. Effects of DNA intercalating agents on topoisomerase II induced DNA strand cleavage in isolated mammalian cell nuclei. Biochemistry, 24: 6406-6410, 1985.
31. Tewey, K. M., Rowe, T. C., Yang, L., Halligan, B. D., and Liu, L. F. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science (Washington, DC), 226: 466-468, 1984.
32. Miller, T. P., Grogan, T. M., Dalton, W. S., Spier, C. M., Scheper, R. J., and Salmon, S. E. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J. Clin. Oncol., 9: 17-24, 1991.
33. Chabner, B. A., and Fojo, A. Multidrug resistance: P-glycoprotein and its allies-the elusive foes. J. Natl. Cancer Inst., 81: 910-913, 1989.
34. Slovak, M. L., Hoeltge, G. A., Dalton, W. S., and Trent, J. M. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines. Cancer Res., 48: 2793-2797, 1988.
35. Cass, C. E., Janowska-Wieczore, A., Lynch, M. A., Sheinin, H., Hindenburg, A. A., and Beck, W. T. Effect of duration of exposure to verapamil on vincristine activity against multidrug-resistant human leukemic cell lines. Cancer Res., 49: 5798-5804, 1989.
36. McGrath, T., and Center, M. S. Adriamycin resistance in HL60 cells in the absence of detectable P-glycoprotein. Biochem. Biophys. Res. Commun., 145: 1171-1176, 1987.
37. Baas, F., Jongsma, A. P. M., Broxterman, H. J., Arceci, R. J., Housman, D., Scheffer, G. L., Riethorst, A., van Groenigen, M., Nieuwint, A. W. M., and Joenje, H. Non-P-glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in a human lung cancer cell line. Cancer Res., 50: 5392-5398, 1990.
38. Reeve, J. G., Rabbitts, P. H., and Twentyman, P. R. Non-P-glycoprotein-mediated multidrug resistance with reduced EGF receptor expression in a human large cell lung cancer cell line. Br. J. Cancer, 61: 851-855, 1990.
39. Keizer, H. G., Schuurhuis, G. J., Broxterman, H. J., Lankelma, J., Schoonen, W. G. E. J., van Rijn, J., Pinedo, H. M., and Joenje, H. Correlation of multidrug resistance with decreased drug accumulation, altered subcellular drug distribution, and increased P-glycoprotein expression in cultured SW-1573 human lung tumor cells. Cancer Res., 49: 2988-2993, 1989.
40. Willingham, M. C., Cornwell, M. M., Cardarelli, C. O., Gottesman, M. M., and Pastan, I. Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive KB cells: effects of verapamil and other drugs. Cancer Res., 46: 5941-5946, 1986.
41. Hindenburg, A. A., Gervasoni, J. E., Jr., Krishna. S., Stewart, V. J., Rosado, M., Lutzky, J., Bhalla, K., Baker, M. A., and Taub, R. N. Intracellular distribution and pharmacokinetics of daunorubicin in anthracycline-sensitive and -resistant HL-60 cells. Cancer Res., 9:4607-4614. 1989.
42. Goldenberg, G. J., Wang, H., and Blair. G. Resistance to Adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and doublestrand breakage in cloned cell lines of Adriamycin-sensitive and -resistant P388 leukemia. Cancer Res., 46: 2978-2983, 1986.
43. Capranico, G., Riva, A., Tinelli, S., Dasdia, T., and Zunino, F. Markedly reduced levels of anthracycline-induced DNA strand breaks in resistant P388 leukemia cells and isolated nuclei. Cancer Res., 47: 3752-3756, 1987.
44. Zwelling, L. A., Slovak, M. L., Hinds. M., Chan, D., Parker, E., Mayes, J., Sie, K. L., Meltzer, P. S., and Trent, J. M. HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase Il-reactive drugs despite the presence of a drug-sensitive topoisomerase II. J. Natl. Cancer Inst., 82: 1553-1561, 1990.
45. Broggini, M., Grandi, M., Ubezio, P., Geroni, C., Giuliani, F. C., and D'Incalci, M. Intracellular doxorubicin concentrations and drug-induced DNA damage in a human colon adenocarcinoma cell line and in a drug-resistant subline. Biochem. Pharmacol., J7: 4423-4431, 1988.
46. Deffie, A. M., Alam, T., Seneviratne, C., Beenken, S. W., Batra, J. K., Shea, T. C., Henner, W. D., and Goldenberg. G. J. Multifactorial resistance to Adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of Adriamycin-sensitive and -resistant P388 leukemia. Cancer Res., 48: 3595-3602, 1988.
47. Beck, V.Y.T. Unknotting the complexities of multidrug resistance: the involvement of DNA topoisomerases in drug action and resistance. J. Natl. Cancer Inst., 81: 1683-1685, 1989.
48. Drake, F. H., Zimmerman. J. P., McCabe, F. L., Barus, H. F., Per, S. R., Sullivan, D. M., Ross, W. E., Mattern, M. R., Johnson, R. K., Crooke, S. T., and Mirabelli, C. K. Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme. J. Biol. Chem., 262: 16739-16747. 1987.
49. Chung. T. D. Y., Drake, F. H., Tan, K. B., Per. S. R., Crooke, S. T., and Mirabelli, C. K. Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes. Proc. Natl. Acad. Sci. USA. 86: 9431-9435. 1989. '
50. Fernandes, D. J., Danks, M. K., and Beck, Y. T. Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSA. Biochemistry. 29:4235-4241. 1990.
51. Deffie, A. M., Bosman, D. J., and Goldenberg, G. J. Evidence for a mutant allele of the gene for DNA topoisomerase II in Adriamycin-resistant P388 murine leukemia cells. Cancer Res., 49: 6879-6882, 1989.
52. Zwelling. L. A., Hinds. M., Chan. D., Mayes. J., Sie. K. L., Parker. E., Silverman, L., Radcliffe, A., Beran, M., and Blick. M. Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II. J. Biol. Chem., 264: 16411-16420, 1989.
53. Tan, K. B., Mattern, M. R., Eng, W.-K., McCabe, F. L., and Johnson, R. K. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J. Natl. Cancer Inst., 81: 1732-1735, 1989.
54. Batist. G., Tulpuli. A., Sinha. B. K., Katki, A. G., Myers. C. E., and Cowan, K. H. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J. Biol. Chem., 261:15544-15549, 1986.
55. Binaschi, M., Capranico, G., De Isabella, P., Mariani, M., Supino, R., Tinelli, S., and Zunino. F. Comparison of DNA cleavage induced by etoposide and doxorubicin in two human small-cell lung cancer lines with different sensitivities to topoisomerase II inhibitors. Int. J. Cancer. 45: 347-352. 1990.
56. Campling. B. G., Pym, J., Baker, H. M., Cole, S. P. C., and Lam, Y.-M. Chemosensitivity testing of small cell lung cancer using the MTT assay. Br. J. Cancer. 63: 75-83. 1991.